News Sentiment

GANX sentiment intelligence

Gain Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 64 Constructive news tone 56 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.80 Week of 10 Jul 2026
Weighted tone 64/100

Constructive news tone

Market reaction Positive news being faded

Constructive headlines are not being rewarded by price, which raises a rejection flag.

Primary event Market update

76/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-5.8% over one week, +7.1% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Gain Therapeutics (GANX) awards director 25,000 stock options at $1.68

Market Reaction

Positive news being faded

73/100 confidence

Constructive headlines are not being rewarded by price, which raises a rejection flag.

Primary event Market update 76/100 classification
One-week reaction -5.8% Price reacting lower
Trend fit Trend inactive 7.1% over four weeks
Fair value -24.3% Below fair value
Sentiment-trend disagreement Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 38
Neutral 14
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
Market source 9
TradingView 9
Moomoo 4
GlobeNewswire 3
Quartr 3
simplywall.st 3
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 24
Earnings 19
Regulatory and legal 8
Analyst action 5

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 56
Pluang Direct company coverage

Gain Therapeutics advances Parkinson's drug rexaceract with positive Phase 1b data and plans Phase 2 start in Q3 2026

Gain Therapeutics announced positive Phase 1b clinical trial results for its Parkinson's drug candidate, rexaceract, demonstrating safety, tolerability, and initial signs of efficacy. The FDA has approved its Investigational New Drug application, allowing the company to proceed w

Tone
Positive 92/100
Event
Regulatory and legal
Published
16 Jul 2026 11:41
Source
Pluang
TradingView Direct company coverage

Gain Therapeutics says cash runway extends into Q2 2027 amid Phase 2 start plans

Gain Therapeutics (GANX) announced that its current cash and cash equivalents are projected to fund operations into the second quarter of 2027. This financial outlook is based on existing operating plans, including the completion of a Phase 1b open-label extension in October 2026

Tone
Positive 71/100
Event
Earnings
Published
16 Jul 2026 11:41
Source
TradingView
Stock Titan Direct company coverage

Gain Therapeutics (NASDAQ: GANX) sees cash funding into Q2 2027

Gain Therapeutics (NASDAQ: GANX) announced that its current cash and cash equivalents are expected to fund operations into the second quarter of 2027 based on its current operating plans. This cash runway supports the completion of a Phase 1b open-label extension in October 2026

Tone
Positive 61/100
Event
Earnings
Published
16 Jul 2026 11:41
Source
Stock Titan
Investing.com Canada Direct company coverage

Gain Therapeutics plans phase 2 Parkinson’s study in Q3 2026 By Investing.com

Gain Therapeutics (NASDAQ:GANX) announced it received FDA authorization to begin a Phase 2 clinical study for rexaceract, its Parkinson’s disease treatment, in Q3 2026. The company reported positive results from its ongoing Phase 1b extension study, with all participants continui

Tone
Positive 65/100
Event
Earnings
Published
16 Jul 2026 10:41
Source
Investing.com Canada
Quartr Direct company coverage

Gain Therapeutics (GANX) Q1 2026 earnings summary

Gain Therapeutics (GANX) reported a Q1 2026 net loss of $5.6 million, or $0.13 per share, with increased R&D and G&A expenses due primarily to the GT-02287 program for Parkinson's disease. The company anticipates IND clearance for GT-02287 in Q2 2026 and Phase 2 trial initiation

Tone
Negative 36/100
Event
Earnings
Published
13 Jul 2026 05:10
Source
Quartr
Quartr Direct company coverage

Gain Therapeutics (GANX) Q4 2025 earnings summary

Gain Therapeutics (GANX) reported its Q4 2025 earnings, highlighting advancements in its Parkinson's disease candidate, GT-02287, which showed promising Phase 1b data and disease-modifying potential. The company saw a decrease in both R&D and G&A expenses, leading to a slightly r

Tone
Positive 74/100
Event
Earnings
Published
12 Jul 2026 16:40
Source
Quartr
Quartr Direct company coverage

Gain Therapeutics (GANX) The 38th Annual Roth Conference Summary

This article summarizes Gain Therapeutics' presentation at the 38th Annual Roth Conference, focusing on their therapeutic approach for Parkinson's disease. The company uses its Magellan platform to develop GT-02287, a drug designed to stabilize the GCase protein and modify the di

Tone
Positive 91/100
Event
Market update
Published
12 Jul 2026 11:39
Source
Quartr
Parkinson's News Today Direct company coverage

With new FDA green light for developer, Parkinson’s clinical trial to launch soon

The FDA has approved Gain Therapeutics to begin a clinical trial for its oral Parkinson's therapy, GT-02287. This therapy aims to prevent toxic protein clumps from forming in the brain by restoring the activity of the GCase enzyme. Previous studies showed GT-02287 to be safe and

Tone
Positive 86/100
Event
Market update
Published
07 Jul 2026 04:09
Source
Parkinson's News Today
TradingView Direct company coverage

Enterprise value to EBIT forward of Gain Therapeutics, Inc. – NASDAQ:GANX

The article provides a financial metric for Gain Therapeutics, Inc. (NASDAQ: GANX), specifically its enterprise value to EBIT (Earnings Before Interest and Taxes) forward. It appears to be a stub or partial financial data point from TradingView, indicating a period value, and cha

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 15:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Gain Therapeutics, Inc. – NASDAQ:GANX

This article provides the enterprise value to revenue forward for Gain Therapeutics, Inc. (NASDAQ: GANX). The financial data is available on TradingView, which also provides additional market and company information.

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 07:40
Source
TradingView
BioBuzz Direct company coverage

Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease

Gain Therapeutics announced that the FDA has cleared its Investigational New Drug (IND) application for GT-02287, allowing it to advance into Phase 2 clinical development for Parkinson’s disease in the U.S. This decision follows positive Phase 1 results demonstrating favorable sa

Tone
Positive 74/100
Event
Regulatory and legal
Published
02 Jul 2026 03:39
Source
BioBuzz
Investing.com Direct company coverage

H.C. Wainwright reiterates Gain Therapeutics stock rating on FDA approval

H.C. Wainwright has reiterated a Buy rating and an $8.00 price target for Gain Therapeutics (NASDAQ:GANX) after the FDA authorized the company's Investigational New Drug application for GT-02287. This FDA decision allows Gain Therapeutics to initiate Phase 2 clinical assessment i

Tone
Positive 92/100
Event
Regulatory and legal
Published
02 Jul 2026 02:11
Source
Investing.com
Moomoo Direct company coverage

Gain Therapeutics Is Maintained at Buy by BTIG

BTIG has reiterated its Buy rating for Gain Therapeutics (NASDAQ:GANX). The article does not provide a specific price target or further details on the analyst's rationale.

Tone
Positive 68/100
Event
Analyst action
Published
01 Jul 2026 14:42
Source
Moomoo
GuruFocus Direct company coverage

GANX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00

HC Wainwright & Co. has reiterated its 'Buy' rating for Gain Therapeutics (GANX), maintaining a price target of $8.00, significantly higher than its current trading price of $2.03. While the company's GF Score of 32/100 indicates potential weaknesses in profitability and growth,

Tone
Positive 71/100
Event
Analyst action
Published
01 Jul 2026 13:39
Source
GuruFocus
Moomoo Direct company coverage

Stocks to Watch: AeroVironment, Concentrix, Gain Therapeutics, Praxis Precision Medicines

This article highlights several stocks for investors to watch, including AeroVironment (AVAV), Concentrix (CNXC), Gain Therapeutics (GANX), and Praxis Precision Medicines (PRAX). Each company's stock is experiencing specific market movements or has upcoming events that could impa

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 13:11
Source
Moomoo
Moomoo Direct company coverage

Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 Into Phase 2 Development for Parkinson's Disease

Gain Therapeutics announced that the FDA has cleared its Investigational New Drug (IND) application for GT-02287, allowing the company to proceed with Phase 2 clinical trials for Parkinson's disease. GT-02287 is a brain-penetrant allosteric activator of GCase, designed to address

Tone
Positive 72/100
Event
Regulatory and legal
Published
30 Jun 2026 12:39
Source
Moomoo
TradingView Direct company coverage

Number of shareholders of Gain Therapeutics, Inc. – NASDAQ:GANX

This article provides information on the number of shareholders for Gain Therapeutics, Inc. (NASDAQ: GANX). It is a financial data point from TradingView, which aggregates market data from various sources. The article itself does not provide the specific number of shareholders, b

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 12:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Gain Therapeutics, Inc. – NASDAQ:GANX

The article focuses on the "Price to sales forward" metric for Gain Therapeutics, Inc. (NASDAQ: GANX). It presents financial data related to this metric, indicating its value, change, and percentage change over a specified period. The information is provided by TradingView, with

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 08:10
Source
TradingView